• Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • White paper
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
Inhalation
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • White paper
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
  • Bolagsanalys
  • Pressmeddelanden
  • Prenumerera
  • IPO 2017
  • Finansiering
  • Finansiella rapporter
  • Kalender
  • Ägarlista
  • Bolagstämma
  • Bolagsstyrning
  • Presentationer

Inhalation Sciences tidigarelägger delårsrapporten för perioden jan – mar 2025

Inhalation Sciences Sweden AB (publ) ("Bolaget") har beslutat att tidigarelägga publicering av delårsrapporten för perioden januari – mars 2025.

Delårsrapporten för perioden januari – mars 2025 var planerad att offentliggöras den 28 maj 2025, men flyttas till publicering den 16 maj 2025. Anledningen till att delårsrapporten tidigareläggs är för att rapporten har färdigställts tidigare än förväntat.

Bolagets finansiella kalender har uppdaterats och återfinns på: https://www.inhalation.se/investors/kalender/
 

För ytterligare information, kontakta:

Manoush Masarrat, VD
Tel: +46 (0) 73 628 9153
E-post: manoush.masarrat@inhalation.se

Om Inhalation Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) utvecklar och kommersialiserar världsledande instrument för forskning inom inhalation. Bolagets patenterade labbinstrument, PreciseInhale® erbjuder forskare möjligheten att, med mycket hög precision, karakterisera hur aerosoler och små partiklar påverkar våra lungor och därmed vår hälsa när dessa inandas.

Press release in PDF format
Contact

Hälsovägen 7
Novum Floor 6, Elevator E
141 57 Huddinge, Sweden.
contact@inhalation.se
+46 (0) 705 625 195

Visitor entrance: Blickagången 6, Floor 6, Elevator E

Useful links
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • White paper
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
About Us

Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.

Privacy policy

Copyright © 2026 Inhalation. All rights reserved.

Design mkmedia
Contact us!
To top